What Is the New Treatment for Ulcerative Colitis: New FDA Approvals
What is the new treatment for ulcerative colitis? This article covers the newest FDA approved treatments and the experimental therapies. Stay up to date with the latest in managing this chronic condition.
Quick Facts
Mirikizumab and Tofacitinib are the latest FDA approvals for ulcerative colitis treatments, targeting inflammation in patients with moderately to severely active disease.
Biologics like Ustekinumab and newer ones are more targeted than traditional treatments.
Fecal microbiota transplantation and stem cell therapy are being tested in clinical trials to improve outcomes for ulcerative colitis patients.
What is Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the large intestine, causing inflammation and ulcers in the colon and rectum. The cause of UC is unknown but is thought to be an abnormal immune response which causes chronic inflammation and damage to the intestinal lining. It can affect anyone of any age, sex or ethnicity but is more common in people of European descent.
Symptoms of ulcerative colitis can be very different in severity and may include:
Diarrhea with blood and mucus
Abdominal pain and cramping
Urgency and frequency of bowel movements
Weight loss and fatigue
Loss of appetite
In addition to these symptoms, UC can also lead to other health issues like osteoporosis, arthritis and colon cancer. If left untreated UC can lead to serious complications like narrowing of the colon, bowel obstruction and colon cancer. Understanding these aspects of UC is key to managing and treating.
New FDA Approved Treatments for Ulcerative Colitis
New FDA approved treatments for ulcerative colitis bring new hope and new options.
Two of the newest treatments to get FDA approval are Mirikizumab (Omvoh) and Tofacitinib (Xeljanz). These medications target specific parts of the immune system and reduce inflammation. The primary endpoint of the clinical trials for these treatments was clinical remission and secondary endpoint was endoscopic improvement.
Here’s more about these new treatments.
Mirikizumab (Omvoh)
Mirikizumab is a monoclonal antibody that is an interleukin-23p19 antagonist, targeting a part of the immune system involved in inflammation. This mechanism manages moderate to severe ulcerative colitis by reducing the inflammatory response of the disease.
FDA approved in 2023, Mirikizumab can be given via IV infusion or subcutaneous injection, offers flexibility in treatment. This new medicine is an additional tool in managing ulcerative colitis. Mirikizumab can also be used as maintenance therapy to achieve sustained clinical remission.
Tofacitinib (Xeljanz)
Tofacitinib, known as Xeljanz is a JAK inhibitor which got FDA approval for moderate to severe ulcerative colitis in 2018. Tofacitinib blocks the Janus kinase (JAK) enzyme which is involved in reducing inflammation.
One of the benefits of Tofacitinib is oral administration, makes it a long term treatment option for patients. Its effectiveness in reducing inflammation and symptoms has made it a favorite among doctors and patients.
Biologics: The New Way
Biologics have changed the way we treat ulcerative colitis. Designed to target specific parts of the immune system that cause inflammation, these medicines are more focused and effective than traditional treatments. Mirikizumab was the first new biologic for ulcerative colitis in over 15 years, that’s how big a deal these are.
Made from engineered proteins or natural substances, biologics work with the immune system in precise ways. From TNF blockers like vedolizumab that prevent white blood cells from entering the gut to other targeted treatments, biologics have options for every patient.
Ustekinumab (Stelara)
Ustekinumab is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines involved in the inflammatory process. This makes it good for severe ulcerative colitis and other conditions like plaque psoriasis and psoriatic arthritis.
Ustekinumab treatment starts with IV infusion and then subcutaneous injections for maintenance. This approach helps achieve and maintain clinical remission, good for patients with severely active ulcerative colitis.
Choosing a Biologic
Choosing the right biologic depends on disease severity and patient preference. According to AGA, biologics like infliximab and vedolizumab are recommended for moderate to severe ulcerative colitis. Infliximab is given via IV infusion, adalimumab is given as subcutaneous injection, different modes of administration.
Some patients may prefer adalimumab because of self-administration, which gives more flexibility in managing their treatment. Ultimately a doctor should help choose the biologic for each patient.
Biosimilars: Cost Savers
Biosimilars mimic biologics, offer cost effective therapy. In the US, biosimilars like Inflectra, Renflexis and Avsola are available as alternatives to Remicade, one of the most widely used biologic for ulcerative colitis.
One of the biggest advantage of biosimilars is the potential to reduce treatment cost. For example, Remicade biosimilars cost from $600 to $1,100 per 100mg compared to $4,000 to $7,000 for Remicade itself. That’s a big savings for patients and doctors looking to manage cost without compromising efficacy.
New Therapies in Ulcerative Colitis Clinical Trials
Clinical trials are moving forward with new treatments, giving hope to patients who are not responding to current therapies. 90% of patients were in clinical remission after 2 years on Omvoh, that’s how good new clinical trial treatments are. In these trials, patients are randomized into treatment groups receiving the medication or placebo to test the safety and efficacy of the new drug.
Many clinical trials are ongoing to improve the outlook for ulcerative colitis patients. Patients should join these trials to get access to latest treatments and help advance medical knowledge.
Fecal Microbiota Transplantation
Fecal microbiota transplantation (FMT) is an experimental procedure that involves transferring healthy bacteria from a donor’s stool to a patient with ulcerative colitis. This aims to restore the healthy gut microbiome, improve symptoms and heal.
While promising, FMT has challenges in donor selection and administration. More research and clinical trials are needed to address these issues and prove efficacy.
Stem Cell Therapy
Stem cell therapy is another option for ulcerative colitis. This will reduce inflammation and heal damaged tissues, which is key to managing the disease.
Research shows stem cells can achieve sustained clinical remission, long term symptom relief. Ongoing clinical trials to prove stem cell therapy as a treatment option for this tough condition.
Immunomodulators and How They Work
Immunomodulators are used to treat ulcerative colitis by suppressing the immune system to prevent inflammation. These are prescribed when symptoms are not controlled by aminosalicylates.
Sometimes immunomodulators are combined with biologics to increase treatment efficacy and reduce antibody development. This combination is good for patients with severe or refractory ulcerative colitis.
Knowing the risk of ulcerative colitis such as cancer or death highlights the importance of immunomodulators in managing those risks.
Corticosteroids for Flare Ups
Corticosteroids are used for rapid relief of flare ups in ulcerative colitis and severe uc. These powerful anti-inflammatory drugs give quick relief but have long term risks like osteoporosis, high blood pressure and increased infection risk.
Common oral corticosteroids like prednisone and budesonide are used to manage acute symptoms. But tapering off these meds gradually is crucial to allow the adrenal glands to produce natural cortisol again. Patients may also experience side effects like urinary tract infection.
Aminosalicylates for Mild to Moderate UC
Aminosalicylates are the first line of treatment for mild to moderate ulcerative colitis. Medications like mesalamine, sulfasalazine and olsalazine reduce intestinal inflammation and heal. Aminosalicylates induce and maintain remission, that’s why they are the backbone of ulcerative colitis treatment.
Their local bowel action means fewer systemic side effects, good safety profile. Knowing the racial and ethnic distribution of UC is important as it shows the different impact of the disease across different demographics and emphasizes the need for personalized approach.
Ulcerative Colitis Management
Managing ulcerative colitis is a multi-faceted approach that involves medications, lifestyle changes and sometimes surgery. The goal of treatment is to induce and maintain clinical remission which means no symptoms and no inflammation in the colon.
Medications used for UC:
Aminosalicylates (5-ASA drugs): Reduces inflammation in the intestinal lining.
Corticosteroids: Used to calm flare ups quickly but not for long term use due to side effects.
Immunomodulators: Suppresses the immune system to prevent ongoing inflammation.
Biologics: Targets specific proteins involved in the inflammatory process, more targeted treatment.
JAK inhibitors: Blocks the Janus kinase enzyme which is involved in the immune system’s inflammatory response.
Besides medication, lifestyle changes can also impact UC management. These are:
Healthy diet: Eat low fiber high protein diet to reduce colon irritation.
Stay hydrated: Drink plenty of water to manage symptoms.
Avoid trigger foods: Identify and avoid foods that trigger symptoms.
Regular exercise: Reduces stress and overall health.
Adequate sleep: Regulates the immune system and overall well being.
In severe cases surgery may be needed to remove the affected part of the colon or to address complications like bowel obstruction. A personalized approach can help manage UC and improve quality of life.
Emerging Therapies
The future of ulcerative colitis treatment looks promising with several emerging therapies in the pipeline. Clinical trials are exploring new approaches like fecal microbiota transplantation and stem cell therapy which have shown to reduce symptoms and induce sustained clinical remission.
These new treatments are for patients who are not responding to existing treatments, so there’s hope for those with ulcerative colitis.
Ulcerative Colitis: Patient Resources
Living with ulcerative colitis is tough but there are many resources to help patients manage their condition and improve their quality of life. Here are some:
Crohn’s and Colitis Foundation: A non-profit organization that provides education, support and advocacy for people with inflammatory bowel diseases.
American Gastroenterological Association (AGA): Provides education and resources for both healthcare professionals and patients with gastrointestinal disorders.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): A government agency that provides information and resources on digestive diseases including UC.
Ulcerative Colitis Support Group: Online community where people with UC can connect, share and find support.
Healthcare Professional: Consulting a doctor or nurse gastroenterologist is important for personalized care and advice.
Patients with ulcerative colitis should work closely with their healthcare professional to develop a treatment plan that suits their needs and goals. With the right treatment and support managing UC and improving quality of life is possible.
Conclusion
In summary, the treatment landscape for ulcerative colitis is changing fast with new FDA approved medications, biologics, biosimilars and new therapies in clinical trials. These offer more options to manage this chronic disease and hope and better outcomes for patients.
Looking forward, these treatments will bring even more solutions and better quality of life for those with ulcerative colitis. Stay informed, consult with healthcare providers and consider joining clinical trials to find the best treatment for you.
FAQs
What is the latest FDA approved treatment for ulcerative colitis?
The latest FDA approved treatments for ulcerative colitis are Mirikizumab (Omvoh) and Tofacitinib (Xeljanz). Consult with a healthcare provider to find the best option for you.
How are biologics different from traditional ulcerative colitis treatments?
Biologics are different from traditional ulcerative colitis treatments as they target specific parts of the immune system that cause inflammation, hence a more targeted and effective approach.
What are biosimilars and how do they help patients with ulcerative colitis?
Biosimilars are cheaper alternatives to biologics that offer similar benefits to patients with ulcerative colitis and help reduce treatment costs and increase access to treatment.
What are the benefits of fecal microbiota transplantation for ulcerative colitis?
Fecal microbiota transplantation can restore a healthy gut microbiome and improve symptoms and healing in ulcerative colitis patients. This is a potential treatment option for the condition.
Why clinical trials for ulcerative colitis?
Clinical trials are important for new treatments for ulcerative colitis as patients can get access to new therapies that may not be available through standard treatment. These trials ensure new options are proven and safe before they reach the wider patient population.